APA (7th ed.) Citation

Kabirian, R., Tredan, O., Marmé, F., Paoletti, X., Eberst, L., Lebreton, C., . . . Leary, A. (2024). TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer: Clinical trial protocol. Future oncology. https://doi.org/10.1080/14796694.2024.2386922

Chicago Style (17th ed.) Citation

Kabirian, Rayan, et al. "TEDOVA: Vaccine OSE2101 +/- Pembrolizumab as Maintenance in Platinum-sensitive Recurrent Ovarian Cancer: Clinical Trial Protocol." Future Oncology 2024. https://doi.org/10.1080/14796694.2024.2386922.

MLA (9th ed.) Citation

Kabirian, Rayan, et al. "TEDOVA: Vaccine OSE2101 +/- Pembrolizumab as Maintenance in Platinum-sensitive Recurrent Ovarian Cancer: Clinical Trial Protocol." Future Oncology, 2024, https://doi.org/10.1080/14796694.2024.2386922.